World Markets
MRK

FDA Approves Sanofi And Merck's Pediatric Hexavalent Combination Vaccine Vaxelis

An image of a pen on an open laptop
Credit: Shutterstock photo

(RTTNews.com) - The U.S. Food and Drug Administration has approved VAXELIS for use in children from 6 weeks through 4 years of age (prior to the 5th birthday). Vaxelis was developed as part of a joint-partnership between Sanofi and Merck & Co ( MRK ).

VAXELIS is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine.

Sanofi and Merck are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand. Commercial supply will not be available in the U.S. prior to 2020.

Vaxelis is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Read the original article on RTTNews (http://www.rttnews.com/2965483/fda-approves-sanofi-and-merck-s-pediatric-hexavalent-combination-vaccine-vaxelis.aspx)

For comments and feedback: contact editorial@rttnews.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRK

Other Topics

Stocks Economy

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More